“We’re honored that a highly respected research organization like UCL selected Phlexglobal for their eTMF solution,” said John McNeill, Chief Executive Officer of Phlexglobal. “I applaud their targeted efforts to help develop COVID-19 therapies and many other critical health concerns. I would like to also congratulate our Phlexglobal employees, all of whom have made tremendous contributions and a truly extraordinary effort since the start of the pandemic. That is the heart of what will carry us through successfully to the other side of this crisis.”
# # #
Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 13,000 staff and 42,000 students from 150 different countries.
The Institute of Clinical Trials and Methodology at UCL is a centre of excellence for clinical trials, meta‑analysis and epidemiological studies. It has a focus on developing and delivering innovations in methodology that improve and enhance these studies.
The Institute is a pre-eminent centre for clinical trials and amongst the largest of its kind in Europe. It is part of the Faculty of Population Health Sciences in the School of Life and Medical Sciences, and is comprised of four clinical trials units:
- Cancer Research UK & UCL Cancer Trials Centre (virtual)
- Comprehensive Clinical Trials Unit at UCL
- Medical Research Council Clinical Trials Unit at UCL
- PRIMENT Clinical Trials Unit (virtual)
For more information please visit https://www.ucl.ac.uk/